PARP1 and neoplasm: When tumour pathology was assessed, Parp1−/− cRb−/− RasV12 tumours showed lower phospho-histone H3 staining than Parp1+/+ cRb−/− RasV12 tumours (Figure 3B), a finding that suggests a decreased proliferation rate in the former.